igforum.bio / ocrevus-after-one-year-on-the-market-what-do-we-know-now-everyday-health - 19220
A
%Begin  Ocrevus After One Year on the Market  What Do We Know Now   Everyday Health MenuNewslettersSearch Multiple Sclerosis
News
 <h1>Ocrevus After One Year on the Market  What Do We Know Now </h1>Some 30,000 prescriptions for Ocrevus have been written since its approval. Is it living up to its promise?
%Begin  Ocrevus After One Year on the Market What Do We Know Now Everyday Health MenuNewslettersSearch Multiple Sclerosis News

Ocrevus After One Year on the Market What Do We Know Now

Some 30,000 prescriptions for Ocrevus have been written since its approval. Is it living up to its promise?
thumb_up Like (29)
comment Reply (3)
share Share
visibility 555 views
thumb_up 29 likes
comment 3 replies
C
Chloe Santos 1 minutes ago
By Christina FrankMedically Reviewed by Samuel Mackenzie, MD, PhDMarch 13, 2018Everyday Health Arc...
D
Dylan Patel 1 minutes ago
According to the National Multiple Sclerosis Society, 85 percent of people with MS have RRMS, while ...
M
By Christina FrankMedically Reviewed by Samuel Mackenzie, MD, PhDMarch 13, 2018Everyday Health ArchiveMedically ReviewedIt’s early days still for the drug Ocrevus, but so far, both prescribers and users remain hopeful.AlamyWhen the FDA approved the drug Ocrevus (ocrelizumab) in March 2017, it was big news in the multiple sclerosis (MS) world. There are approximately 15 other medications—known as disease-modifying treatments, or DMTs — for MS, but they only treat the most common form of MS, called relapsing-remitting multiple sclerosis (RRMS). Ocrevus is groundbreaking because, while it has been very effective for RRMS, it is also the first medication approved to treat primary-progressive multiple sclerosis (PPMS), a less-common form of the disease.
By Christina FrankMedically Reviewed by Samuel Mackenzie, MD, PhDMarch 13, 2018Everyday Health ArchiveMedically ReviewedIt’s early days still for the drug Ocrevus, but so far, both prescribers and users remain hopeful.AlamyWhen the FDA approved the drug Ocrevus (ocrelizumab) in March 2017, it was big news in the multiple sclerosis (MS) world. There are approximately 15 other medications—known as disease-modifying treatments, or DMTs — for MS, but they only treat the most common form of MS, called relapsing-remitting multiple sclerosis (RRMS). Ocrevus is groundbreaking because, while it has been very effective for RRMS, it is also the first medication approved to treat primary-progressive multiple sclerosis (PPMS), a less-common form of the disease.
thumb_up Like (29)
comment Reply (0)
thumb_up 29 likes
J
According to the National Multiple Sclerosis Society, 85 percent of people with MS have RRMS, while 10 to 15 percent are diagnosed with PPMS. Before Ocrevus, there was very little doctors could do for their patients with PPMS other than provide medications and other therapies to treat the symptoms. Nothing slowed the progression of the disease itself.
According to the National Multiple Sclerosis Society, 85 percent of people with MS have RRMS, while 10 to 15 percent are diagnosed with PPMS. Before Ocrevus, there was very little doctors could do for their patients with PPMS other than provide medications and other therapies to treat the symptoms. Nothing slowed the progression of the disease itself.
thumb_up Like (7)
comment Reply (1)
thumb_up 7 likes
comment 1 replies
N
Nathan Chen 8 minutes ago
“We have been waiting, as clinicians who are passionate about our patients, for breakthroughs and ...
H
“We have been waiting, as clinicians who are passionate about our patients, for breakthroughs and FDA approvals in products like Ocrevus to come about,” says Aaron Boster, MD, the systems medical chief and neuroimmunology director of the MS center at OhioHealth Neuroscience in Columbus. “This changes the playing field and it is very exciting.”
RELATED: 10 Essential Facts About Primary-Progressive MS
 <h2>How Is PPMS Different From RRMS </h2>
MS is an autoimmune disease in which the immune system attacks the myelin sheaths that protect nerve fibers in the brain, spinal cord, and optic nerve. The nerve fibers themselves can also be damaged or destroyed.
“We have been waiting, as clinicians who are passionate about our patients, for breakthroughs and FDA approvals in products like Ocrevus to come about,” says Aaron Boster, MD, the systems medical chief and neuroimmunology director of the MS center at OhioHealth Neuroscience in Columbus. “This changes the playing field and it is very exciting.” RELATED: 10 Essential Facts About Primary-Progressive MS

How Is PPMS Different From RRMS

MS is an autoimmune disease in which the immune system attacks the myelin sheaths that protect nerve fibers in the brain, spinal cord, and optic nerve. The nerve fibers themselves can also be damaged or destroyed.
thumb_up Like (28)
comment Reply (1)
thumb_up 28 likes
comment 1 replies
A
Ava White 1 minutes ago
This, in turn, slows or disrupts the transmission of nerve impulses from the brain, causing symptoms...
M
This, in turn, slows or disrupts the transmission of nerve impulses from the brain, causing symptoms including fatigue, tingling and numbness, weakness, vision problems, and difficulty walking. In relapsing-remitting multiple sclerosis, the most common type, symptoms tend to flare periodically, followed by stretches of complete or partial recovery.
This, in turn, slows or disrupts the transmission of nerve impulses from the brain, causing symptoms including fatigue, tingling and numbness, weakness, vision problems, and difficulty walking. In relapsing-remitting multiple sclerosis, the most common type, symptoms tend to flare periodically, followed by stretches of complete or partial recovery.
thumb_up Like (6)
comment Reply (2)
thumb_up 6 likes
comment 2 replies
Z
Zoe Mueller 7 minutes ago
Those with PPMS experience steadily worsening symptoms with few or no recovery periods. Nerve damage...
N
Nathan Chen 12 minutes ago
RELATED: When MS Attacks the Spinal Cord

Don t miss these real-life tips from hundreds of peop...

L
Those with PPMS experience steadily worsening symptoms with few or no recovery periods. Nerve damage is generally more focused in the spinal cord than in the brain and can cause more significant disability than RRMS.
Those with PPMS experience steadily worsening symptoms with few or no recovery periods. Nerve damage is generally more focused in the spinal cord than in the brain and can cause more significant disability than RRMS.
thumb_up Like (12)
comment Reply (2)
thumb_up 12 likes
comment 2 replies
Z
Zoe Mueller 11 minutes ago
RELATED: When MS Attacks the Spinal Cord

Don t miss these real-life tips from hundreds of peop...

W
William Brown 15 minutes ago
Ocrevus targets and destroys a type of B cells called CD20-positive B cells. Results from clinical t...
C
RELATED: When MS Attacks the Spinal Cord

 <h2>Don t miss these real-life tips from hundreds of people who have MS  Go to Tippi MS and learn more </h2>
 <h2>How Ocrevus Works</h2>Because PPMS involves less inflammatory activity and more gradual destruction and loss of nerve fibers, the available DMTs are not effective in slowing the neural damage that occurs in PPMS. For many years, researchers believed only T cells — components of the immune response — were involved in the MS disease process; hence, many of the medications that are available target T cells. Research into Ocrevus revealed that MS also involves B cells, another factor in immune response.
RELATED: When MS Attacks the Spinal Cord

Don t miss these real-life tips from hundreds of people who have MS Go to Tippi MS and learn more

How Ocrevus Works

Because PPMS involves less inflammatory activity and more gradual destruction and loss of nerve fibers, the available DMTs are not effective in slowing the neural damage that occurs in PPMS. For many years, researchers believed only T cells — components of the immune response — were involved in the MS disease process; hence, many of the medications that are available target T cells. Research into Ocrevus revealed that MS also involves B cells, another factor in immune response.
thumb_up Like (8)
comment Reply (0)
thumb_up 8 likes
H
Ocrevus targets and destroys a type of B cells called CD20-positive B cells. Results from clinical trials on Ocrevus are impressive in showing its effectiveness for both forms of the disease. Trials on people with RRMS, known as OPERA I and II, have made Ocrevus a first-line treatment for this form of the disease.
Ocrevus targets and destroys a type of B cells called CD20-positive B cells. Results from clinical trials on Ocrevus are impressive in showing its effectiveness for both forms of the disease. Trials on people with RRMS, known as OPERA I and II, have made Ocrevus a first-line treatment for this form of the disease.
thumb_up Like (28)
comment Reply (1)
thumb_up 28 likes
comment 1 replies
I
Isaac Schmidt 6 minutes ago
Ocrevus showed greater effectiveness when compared with high-dose Rebif (interferon beta-1a) and red...
R
Ocrevus showed greater effectiveness when compared with high-dose Rebif (interferon beta-1a) and reduced the annual relapse rate by 46 and 47 percent over a two-year period. Over 12 and 24 weeks, disability progression was reduced by 43 percent and 37 percent for both time periods and in both studies. The ORATORIO Phase III trial compared Ocrevus to placebo in individuals with PPMS.
Ocrevus showed greater effectiveness when compared with high-dose Rebif (interferon beta-1a) and reduced the annual relapse rate by 46 and 47 percent over a two-year period. Over 12 and 24 weeks, disability progression was reduced by 43 percent and 37 percent for both time periods and in both studies. The ORATORIO Phase III trial compared Ocrevus to placebo in individuals with PPMS.
thumb_up Like (35)
comment Reply (0)
thumb_up 35 likes
L
In this study, the likelihood of confirmed disability progression was reduced by 24 percent for at least 12 weeks and 25 percent for at least 24 weeks. Furthermore, the time it took patients to walk 25 feet (a standard test for progression) was reduced by 29 percent at 120 weeks. <h2>Convenience a Benefit of Ocrevus </h2>
Another thing that makes Ocrevus appealing is the convenience factor.
In this study, the likelihood of confirmed disability progression was reduced by 24 percent for at least 12 weeks and 25 percent for at least 24 weeks. Furthermore, the time it took patients to walk 25 feet (a standard test for progression) was reduced by 29 percent at 120 weeks.

Convenience a Benefit of Ocrevus

Another thing that makes Ocrevus appealing is the convenience factor.
thumb_up Like (13)
comment Reply (3)
thumb_up 13 likes
comment 3 replies
D
Dylan Patel 10 minutes ago
Existing DMTs are administered via pills, injections, or infusions, some requiring daily dosing, som...
C
Chloe Santos 2 minutes ago
“Ocrevus has proved to be very convenient,” says Ellen Lathi, MD, the director of the Elliot Lew...
E
Existing DMTs are administered via pills, injections, or infusions, some requiring daily dosing, some weekly, some every two weeks, and some monthly. Ocrelizumab is given as an infusion twice a year.
Existing DMTs are administered via pills, injections, or infusions, some requiring daily dosing, some weekly, some every two weeks, and some monthly. Ocrelizumab is given as an infusion twice a year.
thumb_up Like (7)
comment Reply (3)
thumb_up 7 likes
comment 3 replies
A
Ava White 40 minutes ago
“Ocrevus has proved to be very convenient,” says Ellen Lathi, MD, the director of the Elliot Lew...
C
Christopher Lee 41 minutes ago
As a precaution, women taking the medication are strongly advised by their physicians to stay up-to-...
B
“Ocrevus has proved to be very convenient,” says Ellen Lathi, MD, the director of the Elliot Lewis Center for Multiple Sclerosis in Wellesley, Massachusetts. “Because you only need an infusion every six months, it allows patients to forget they have MS for 363 days of the year.”
Risks and side effects of Ocrevus are comparable to those of other DMTs, though some research has suggested Ocrevus may raise the risk of breast cancer.
“Ocrevus has proved to be very convenient,” says Ellen Lathi, MD, the director of the Elliot Lewis Center for Multiple Sclerosis in Wellesley, Massachusetts. “Because you only need an infusion every six months, it allows patients to forget they have MS for 363 days of the year.” Risks and side effects of Ocrevus are comparable to those of other DMTs, though some research has suggested Ocrevus may raise the risk of breast cancer.
thumb_up Like (25)
comment Reply (2)
thumb_up 25 likes
comment 2 replies
S
Scarlett Brown 27 minutes ago
As a precaution, women taking the medication are strongly advised by their physicians to stay up-to-...
V
Victoria Lopez 17 minutes ago
Nicodemus received a diagnosis of MS in 2001 and initially chose not to take any medication for it, ...
H
As a precaution, women taking the medication are strongly advised by their physicians to stay up-to-date on mammograms. <h2>Real-world Experiences of People Taking Ocrevus</h2>
According to Genentech, which manufactures the drug, approximately 30,000 prescriptions for Ocrevus have been written since its approval. Among the first people to receive an infusion of the medication is Kani Nicodemus, 52, a fitness instructor in Milford, New Hampshire.
As a precaution, women taking the medication are strongly advised by their physicians to stay up-to-date on mammograms.

Real-world Experiences of People Taking Ocrevus

According to Genentech, which manufactures the drug, approximately 30,000 prescriptions for Ocrevus have been written since its approval. Among the first people to receive an infusion of the medication is Kani Nicodemus, 52, a fitness instructor in Milford, New Hampshire.
thumb_up Like (33)
comment Reply (0)
thumb_up 33 likes
I
Nicodemus received a diagnosis of MS in 2001 and initially chose not to take any medication for it, instead focusing on her diet and exercise regimen. “Until 2008, I didn’t have many symptoms,” she says. “Then I developed neuropathy and fatigue, so my neurologist put me on Gilenya (fingolimod), and after that, Aubagio (teriflumonide).”
In 2013, Nicodemus noticed new symptoms, including mobility issues with her left leg and a condition called “drop foot,” in which you have trouble lifting the front of your foot when you walk.
Nicodemus received a diagnosis of MS in 2001 and initially chose not to take any medication for it, instead focusing on her diet and exercise regimen. “Until 2008, I didn’t have many symptoms,” she says. “Then I developed neuropathy and fatigue, so my neurologist put me on Gilenya (fingolimod), and after that, Aubagio (teriflumonide).” In 2013, Nicodemus noticed new symptoms, including mobility issues with her left leg and a condition called “drop foot,” in which you have trouble lifting the front of your foot when you walk.
thumb_up Like (14)
comment Reply (2)
thumb_up 14 likes
comment 2 replies
S
Sebastian Silva 27 minutes ago
As her symptoms progressed, her doctors came to the conclusion that she likely has PPMS. “There we...
G
Grace Liu 50 minutes ago
“Two months later, I started Ocrevus. There hasn’t been any further progression, and my symptoms...
J
As her symptoms progressed, her doctors came to the conclusion that she likely has PPMS. “There were no treatments for PPMS available during that time, so I continued with Aubagio and only discontinued it in January 2017,” says Nicodemus.
As her symptoms progressed, her doctors came to the conclusion that she likely has PPMS. “There were no treatments for PPMS available during that time, so I continued with Aubagio and only discontinued it in January 2017,” says Nicodemus.
thumb_up Like (26)
comment Reply (1)
thumb_up 26 likes
comment 1 replies
D
David Cohen 52 minutes ago
“Two months later, I started Ocrevus. There hasn’t been any further progression, and my symptoms...
M
“Two months later, I started Ocrevus. There hasn’t been any further progression, and my symptoms have been well-controlled. It takes less time for my leg to recover from the drop foot.
“Two months later, I started Ocrevus. There hasn’t been any further progression, and my symptoms have been well-controlled. It takes less time for my leg to recover from the drop foot.
thumb_up Like (11)
comment Reply (1)
thumb_up 11 likes
comment 1 replies
H
Harper Kim 31 minutes ago
For me that’s a huge benefit, because I am not a sit-still kind of person.” Trish Palmer, 34, of...
A
For me that’s a huge benefit, because I am not a sit-still kind of person.”
Trish Palmer, 34, of Columbus, Ohio, was diagnosed with RRMS in 2013 and had been on three different drugs without much improvement. “I had a very significant relapse in 2015,” she says. After six months on Ocrevus, Palmer feels the drug is working.
For me that’s a huge benefit, because I am not a sit-still kind of person.” Trish Palmer, 34, of Columbus, Ohio, was diagnosed with RRMS in 2013 and had been on three different drugs without much improvement. “I had a very significant relapse in 2015,” she says. After six months on Ocrevus, Palmer feels the drug is working.
thumb_up Like (4)
comment Reply (0)
thumb_up 4 likes
A
“I had a clean MRI, and I’ve been more active in the last few months. I’m starting to feel confident that this is a long-term solution.”
 <h2>Hope for the Future</h2>
It’s too soon to say how things will play out over time, but after one year, Dr.
“I had a clean MRI, and I’ve been more active in the last few months. I’m starting to feel confident that this is a long-term solution.”

Hope for the Future

It’s too soon to say how things will play out over time, but after one year, Dr.
thumb_up Like (47)
comment Reply (1)
thumb_up 47 likes
comment 1 replies
M
Mason Rodriguez 13 minutes ago
Lathi says the drug has gotten an “A-plus” from her patients. Dr....
L
Lathi says the drug has gotten an “A-plus” from her patients. Dr.
Lathi says the drug has gotten an “A-plus” from her patients. Dr.
thumb_up Like (16)
comment Reply (0)
thumb_up 16 likes
A
Boster points out that doctors “can’t reverse damage that’s already been done in patients, but we can halt further progression. I used to tell my patients, ‘I can make you get worse slower.’ Now I can say ‘Let’s make it stop.’ That’s very exciting.”
NEWSLETTERS
 <h3>Sign up for our Multiple Sclerosis Newsletter </h3>SubscribeBy subscribing you agree to the Terms of Use and Privacy Policy.
Boster points out that doctors “can’t reverse damage that’s already been done in patients, but we can halt further progression. I used to tell my patients, ‘I can make you get worse slower.’ Now I can say ‘Let’s make it stop.’ That’s very exciting.” NEWSLETTERS

Sign up for our Multiple Sclerosis Newsletter

SubscribeBy subscribing you agree to the Terms of Use and Privacy Policy.
thumb_up Like (20)
comment Reply (1)
thumb_up 20 likes
comment 1 replies
D
David Cohen 1 minutes ago

The Latest in Multiple Sclerosis

How to Craft a Life s Mission Statement

By Trevis...
L
<h2>The Latest in Multiple Sclerosis</h2>
 <h3>How to Craft a Life s Mission Statement</h3>By Trevis GleasonOctober 21, 2022

 <h3>Dysarthria  When MS Makes It Hard to Speak</h3>By Mona SenOctober 20, 2022
 <h3>Is That Really How I Walk </h3>By Trevis GleasonOctober 18, 2022
 <h3>How Do You Know When to Throw in the Towel </h3>By Trevis GleasonOctober 14, 2022
 <h3>Living With MS  What to Know About Neuropathic Pain  and How to Manage It </h3>Neuropathic pain is not your average pain. Here’s what to know about this unique type of MS pain and how to find relief.By Kerry WeissOctober 12, 2022

 <h3>UTIs and MS  The Importance of Early Diagnosis and Treatment</h3>If you have multiple sclerosis, you may be prone to frequent urinary tract infections. Besides being painful, UTIs can make MS worse, so it’s important...By Kerry WeissOctober 12, 2022

 <h3>Why Is Orange the Color of MS </h3>By Trevis GleasonOctober 11, 2022
 <h3>13 Celebrities Who Have Multiple Sclerosis</h3>Look among the millions of people with multiple sclerosis and you&#x27;ll find famous faces, too.

The Latest in Multiple Sclerosis

How to Craft a Life s Mission Statement

By Trevis GleasonOctober 21, 2022

Dysarthria When MS Makes It Hard to Speak

By Mona SenOctober 20, 2022

Is That Really How I Walk

By Trevis GleasonOctober 18, 2022

How Do You Know When to Throw in the Towel

By Trevis GleasonOctober 14, 2022

Living With MS What to Know About Neuropathic Pain and How to Manage It

Neuropathic pain is not your average pain. Here’s what to know about this unique type of MS pain and how to find relief.By Kerry WeissOctober 12, 2022

UTIs and MS The Importance of Early Diagnosis and Treatment

If you have multiple sclerosis, you may be prone to frequent urinary tract infections. Besides being painful, UTIs can make MS worse, so it’s important...By Kerry WeissOctober 12, 2022

Why Is Orange the Color of MS

By Trevis GleasonOctober 11, 2022

13 Celebrities Who Have Multiple Sclerosis

Look among the millions of people with multiple sclerosis and you'll find famous faces, too.
thumb_up Like (1)
comment Reply (0)
thumb_up 1 likes
N
Learn how some of these celebrities are dealing with MS and...By Regina Boyle WheelerOctober 11, 2022
 <h3>We All Have Something to Teach Our MS Doctors</h3>By Trevis GleasonOctober 7, 2022
 <h3>EBV  An MS Box I Can Finally Tick</h3>By Trevis GleasonOctober 4, 2022 MORE IN
 <h3>10 Essential Facts About Primary-Progressive MS</h3>
 <h3>16 Conditions Commonly Mistaken for Multiple Sclerosis</h3>
 <h3>What Happens if Multiple Sclerosis Goes Untreated </h3>
Learn how some of these celebrities are dealing with MS and...By Regina Boyle WheelerOctober 11, 2022

We All Have Something to Teach Our MS Doctors

By Trevis GleasonOctober 7, 2022

EBV An MS Box I Can Finally Tick

By Trevis GleasonOctober 4, 2022 MORE IN

10 Essential Facts About Primary-Progressive MS

16 Conditions Commonly Mistaken for Multiple Sclerosis

What Happens if Multiple Sclerosis Goes Untreated

thumb_up Like (18)
comment Reply (1)
thumb_up 18 likes
comment 1 replies
D
David Cohen 13 minutes ago
 Ocrevus After One Year on the Market What Do We Know Now Everyday Health MenuNewslettersSearc...

Write a Reply